Authors

Latest:

Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC

Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.

Matthew H. Katz, MD

Latest:

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Matthew H. Kulke, MD

Latest:

Neuroendocrine Tumors: Future Directions in Care

A brief synopsis of future directions in the treatment landscape of advanced neuroendocrine tumors.

Matthew H. Kulke, MD, Dana-Farber Cancer Institute

Latest:

The Nature of Neuroendocrine Tumors

Expert insight on the subtypes of neuroendocrine tumors and current understanding of the disease microenvironment.

Matthew H. Kulke, MD, Harvard Medical School

Matthew H. Kulke, MD, Ochsner Medical Center - Kenner

Matthew H. Taylor, MD, Oregon Health

Latest:

Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid Tumors

Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.

Matthew H.G. Katz, MD

Latest:

Dr. Matthew Katz on Borderline Resectable Pancreatic Cancer

Matthew H.G. Katz, MD, from the MD Anderson Cancer Center, discusses borderline resectable pancreatic ductal adenocarcinoma, a newer stage of pancreatic cancer introduced by the NCCN in 2003.

Matthew H.G. Katz, MD, FACS

Latest:

Dr. Katz on Neoadjuvant Chemotherapy in Pancreatic Cancer

Matthew H.G. Katz, MD, FACS, discusses the benefit of neoadjuvant chemotherapy in patients with pancreatic cancer.

Matthew J. Ellis, MD, PhD

Latest:

Dr. Ellis on Adjuvant CDK4/6 Inhibition in HR-Positive Breast Cancer

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses adjuvant CDK4/6 inhibition in hormone receptor (HR)-positive breast cancer.

Matthew J. Matasar, MD

Latest:

Future Perspectives for the Treatment of Relapsed/Refractory DLBCL

A reflection on key accomplishments in DLBCL treatment, highlighting pivotal developments that have shaped clinical practice, followed by a look ahead to 2025, focusing on areas poised for significant progress and personal goals for the coming year

Matthew Kulke, MD

Latest:

Systemic Therapy: Advanced Neuroendocrine Tumors

After reviewing the goals of therapy in advanced NET management, Matthew H. Kulke, MD, considers optimal treatment selection and sequencing in this setting.

Matthew Ladra, MD

Latest:

Dr. Ladra on the Treatment of Pediatric Esthesioneuroblastoma

Matthew Ladra, MD, director, Pediatric Radiation Oncology, Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, discusses the treatment of esthesioneuroblastoma in children.

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center

Latest:

Practice Patterns and Real Use of Epcoritamab and Glofitamab

A panel of experts discuss the role of odronextamab.

Matthew Mahady

Latest:

As Practice Grows, Competitors Loom

Established just nine years ago via the merger of three specialty practices and 14 physicians, Dayton Physicians Network, an independent, Ohio-based oncology group practice, has experienced rapid growth, fueled in part by increased Medicaid enrollment and profits from their oral drug dispensing program.

Matthew P. Goetz, MD

Latest:

Dr. Goetz on the Impact of the PALOMA-2 Trial in ER+/HER2- Breast Cancer

Matthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.

Matthew P. Goetz, MD, The Mayo Clinic

Matthew P. Schlumbrecht, MD

Latest:

Dr. Schlumbrecht on Treatment in Uterine Leiomyosarcoma

Matthew P. Schlumbrecht, MD, discusses the treatment of women with uterine leiomyosarcoma.

Matthew Powell, MD

Latest:

Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Matthew Powell, MD, Washington University